{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:56Z","timestamp":1786982696215,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s13760-019-01195-3","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T10:15:28Z","timestamp":1563876928000},"page":"325-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-8711","authenticated-orcid":false,"given":"Anastasia","family":"Bougea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Spantideas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Katoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Stefanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"issue":"2","key":"1195_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneurol.2016.204","volume":"13","author":"J Jankovic","year":"2017","unstructured":"Jankovic J (2017) Movement disorders in 2016: progress in Parkinson disease and other movement disorders. Nat Rev Neurol 13(2):76\u201378","journal-title":"Nat Rev Neurol"},{"key":"1195_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/mds.26510","volume":"31","author":"C Marras","year":"2016","unstructured":"Marras C, Chaudhuri KR (2016) Nonmotor features of Parkinson\u2019s disease subtypes. Mov Disord 31:1095\u20131102","journal-title":"Mov Disord"},{"issue":"1","key":"1195_CR3","first-page":"2012","volume":"78","author":"C Tanner","year":"2012","unstructured":"Tanner C, Albers K, Goldman S, Fross R, Leimpeter A, Klingman J et al (2012) Seborrheic dermatitis and risk of future Parkinson\u2019s Disease. Neurology 78(1):2012","journal-title":"Neurology"},{"issue":"5","key":"1195_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaneurol.2016.0022","volume":"73","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Hansen PR, Gislason GH, Thyssen JP (2016) Exploring the association between rosacea and Parkinson disease: a Danish nationwide cohort study. JAMA Neurol 73(5):529\u2013534","journal-title":"JAMA Neurol"},{"key":"1195_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/CCID.S130319","volume":"10","author":"AH Ravn","year":"2017","unstructured":"Ravn AH, Thyssen JP, Egeberg A (2017) Skin disorders in Parkinson\u2019s disease: potential biomarkers and risk factors. Clin Cosmet Investig Dermatol 10:87\u201392","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"1195_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12883-016-0784-z","volume":"17","author":"A Planken","year":"2017","unstructured":"Planken A, Kurvits L, Reimann E, Kadastik- Eerme L, Kingo K, Koks S et al (2017) Looking beyond the brain to improve the pathogenic understanding of Parkinson\u2019s disease: implications of whole transcriptome profiling of Patients\u2019 skin. BMC Neurol 17(1):6","journal-title":"BMC Neurol"},{"issue":"6","key":"1195_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ana.24802","volume":"80","author":"R Inzelberg","year":"2016","unstructured":"Inzelberg R, Flash S, Friedman E, Azizi E (2016) Cutaneous malignant melanoma and Parkinson disease: common pathways? Ann Neurol 80(6):811\u2013820","journal-title":"Ann Neurol"},{"issue":"2","key":"1195_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/DSS.0000000000000591","volume":"42","author":"M Disse","year":"2016","unstructured":"Disse M, Reich H, Lee PK, Schram SS (2016) A review of the association between Parkinson disease and malignant melanoma. Dermatol Surg 42(2):141\u2013146","journal-title":"Dermatol Surg"},{"issue":"23","key":"1195_CR9","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1212\/WNL.0b013e31821e554e","volume":"76","author":"R Liu","year":"2011","unstructured":"Liu R, Gao X, Lu Y, Chen H (2011) Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76(23):2002\u20132009","journal-title":"Neurology"},{"issue":"1","key":"1195_CR10","doi-asserted-by":"publisher","first-page":"a008862","DOI":"10.1101\/cshperspect.a008862","volume":"1","author":"CG Goetz","year":"2011","unstructured":"Goetz CG (2011) The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 1(1):a008862","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"1195_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/practneurol-2015-001107","volume":"15","author":"R Gregory","year":"2015","unstructured":"Gregory R, Miller S (2015) Parkinson\u2019s disease and the skin. Pract Neurol 15(4):246\u2013249","journal-title":"Pract Neurol"},{"key":"1195_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40035-015-0044-y","volume":"4","author":"P Huang","year":"2015","unstructured":"Huang P, Yang XD, Chen SD, Xiao Q (2015) The association between Parkinson\u2019s disease and melanoma: a systematic review and meta-analysis. Transl Neurodegener 4:21","journal-title":"Transl Neurodegener"},{"key":"1195_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"1195_CR14","unstructured":"Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration"},{"key":"1195_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"1195_CR16","first-page":"213","volume":"95","author":"E Robinson","year":"1973","unstructured":"Robinson E, Wajsbort J, Hirshowitz B (1973) Levodopa and malignant melanoma. Arch Pathol 95:213","journal-title":"Arch Pathol"},{"key":"1195_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1212\/WNL.24.4.340","volume":"24","author":"AN Lieberman","year":"1974","unstructured":"Lieberman AN, Shupack JL (1974) Levodopa and melanoma. Neurology 24:340","journal-title":"Neurology"},{"key":"1195_CR18","first-page":"883","volume":"241","author":"AJ Sober","year":"1979","unstructured":"Sober AJ, Wick MM (1979) Levodopa and melanoma. JAMA 241:883\u2013884","journal-title":"JAMA"},{"key":"1195_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/archderm.1980.01640330079019","volume":"116","author":"JE Bernstein","year":"1980","unstructured":"Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL (1980) Levodopa administration and multiple primary cutaneous melanomas. Arch Dermatol 116:1041\u20131044","journal-title":"Arch Dermatol"},{"key":"1195_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0002-9343(85)90555-8","volume":"79","author":"AS Kochar","year":"1985","unstructured":"Kochar AS (1985) Development of malignant melanoma after levodopa therapy for Parkinson\u2019s disease. Am J Med 79:119\u2013121","journal-title":"Am J Med"},{"key":"1195_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/jnnp.48.6.585","volume":"48","author":"FHJ Rampen","year":"1985","unstructured":"Rampen FHJ (1985) Levodopa and melanoma: three cases and review of literature. J Neurol Neurosurg Psychiatry 48:585\u2013588","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1195_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/bjo.76.4.246","volume":"76","author":"SA Haider","year":"1992","unstructured":"Haider SA, Thaller VT (1992) Lid melanoma and parkinsonism. Br J Ophthalmol 76:246\u2013247","journal-title":"Br J Ophthalmol"},{"issue":"2 Pt 2","key":"1195_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0190-9622(97)80385-4","volume":"37","author":"W Pf\u00fctzner","year":"1997","unstructured":"Pf\u00fctzner W, Przybilla B (1997) Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 37(2 Pt 2):332\u2013336","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1195_CR24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1755-148X.2009.00624.x","volume":"22","author":"J Charles","year":"2009","unstructured":"Charles J, Templier I, Leroux D, Leroux D, Salameire D, Robert C, Lantuejoul S et al (2009) Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson\u2019s disease. Pigment Cell Melanoma Res 22(6):851\u2013853","journal-title":"Pigment Cell Melanoma Res"},{"key":"1195_CR25","first-page":"1387","volume":"309","author":"CG Goetz","year":"1983","unstructured":"Goetz CG (1983) Skin rash associated with Sinemet 25\/100. N Engl J Med 309:1387\u20131388","journal-title":"N Engl J Med"},{"issue":"13","key":"1195_CR26","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1212\/01.wnl.0000257823.27573.3d","volume":"68","author":"KL Chou","year":"2007","unstructured":"Chou KL, Stacy MA (2007) Skin rash associated with Sinemet does not equal levodopa allergy. Neurology 68(13):1078\u20131079","journal-title":"Neurology"},{"issue":"2","key":"1195_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/WNF.0000000000000270","volume":"41","author":"MA Cansino-Torres","year":"2018","unstructured":"Cansino-Torres MA, Sandoval-Rodr\u00edguez V, S\u00e1enz-Farret M (2018) Allergy to Carbidopa. Clin Neuropharmacol 41(2):75\u201379","journal-title":"Clin Neuropharmacol"},{"issue":"9058","key":"1195_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0140-6736(05)62294-5","volume":"349","author":"G Niedermaier","year":"1997","unstructured":"Niedermaier G, Briner V (1997) Henoch-Sch\u00f6nlein syndrome induced by carbidopa\/levodopa. Lancet 349(9058):1071\u20131072","journal-title":"Lancet"},{"issue":"1","key":"1195_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/0028-3886.173656","volume":"64","author":"L Esteban-Fernandez","year":"2016","unstructured":"Esteban-Fernandez L, Alonso-Canovas A, Rojas-Medina LM, Ballester-Mart\u00cdnez MA, Corral-Corral I, Martinez-Castrillo JC (2016) Carbidopa-induced eosinophilic fasciitis: A review. Neurol India 64(1):157\u2013159","journal-title":"Neurol India"},{"issue":"2 Pt 1","key":"1195_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0190-9622(08)80475-6","volume":"25","author":"P Joly","year":"1991","unstructured":"Joly P, Lampert A, Thomine E, Lauret P (1991) Development of pseudobullous morphea and scleroderma-like illness during therapy with l-5-hydroxytryptophan and carbidopa. J Am Acad Dermatol 25(2 Pt 1):332\u2013333","journal-title":"J Am Acad Dermatol"},{"key":"1195_CR31","first-page":"97","volume":"1","author":"KM Grainger","year":"1971","unstructured":"Grainger KM (1971) Pigmentation in Parkinson\u2019s disease treated with levodopa. Lancet 1:97\u201398","journal-title":"Lancet"},{"issue":"4","key":"1195_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2230.1989.tb01992.x","volume":"14","author":"NJ Reynolds","year":"1989","unstructured":"Reynolds NJ, Crossley J, Ferguson I, Peachey RD (1989) Darkening of white hair in Parkinson\u2019s disease. Clin Exp Dermatol 14(4):317\u2013318","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1195_CR33","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/mds.25696","volume":"28","author":"T Komagamine","year":"2013","unstructured":"Komagamine T, Suzuki K, Hirata K (2013) Darkening of white hair following levodopa therapy in a patient with Parkinson\u2019s disease. Mov Disord 28(12):1643","journal-title":"Mov Disord"},{"issue":"2","key":"1195_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/S0004-282X2013000200018","volume":"71","author":"RP Munhoz","year":"2013","unstructured":"Munhoz RP, Teive HA (2013) Darkening of white hair in Parkinson\u2019s disease during use of levodopa rich Mucuna pruriens extract powder. Arq Neuropsiquiatr 71(2):133","journal-title":"Arq Neuropsiquiatr"},{"issue":"3","key":"1195_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1468-3083.2003.00431.x","volume":"17","author":"J Vega Guti\u00e9rrez","year":"2003","unstructured":"Vega Guti\u00e9rrez J, Miranda Romero A, Mart\u00ednez G, Torrero MV, Lopez de Juan M (2003) Hyperpigmentation mimicking Laugier syndrome, levodopa therapy and Addison\u2019s disease. J Eur Acad Dermatol Venereol 17(3):324\u2013327","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1195_CR36","first-page":"1228","volume":"33","author":"M Sabat\u00e9","year":"1999","unstructured":"Sabat\u00e9 M, Bosch A, Pedr\u00f3s C, Figueras A (1999) Vitiligo associated with tolcapone and levodopa in a patient with Parkinson\u2019s disease. Ann Pharmacother 33(11):1228\u20131229","journal-title":"Ann Pharmacother"},{"issue":"5752","key":"1195_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/bmj.2.5752.47","volume":"2","author":"A Marshall","year":"1971","unstructured":"Marshall A, Williams MJ (1971) Alopecia and levodopa. Br Med J 2(5752):47","journal-title":"Br Med J"},{"issue":"1","key":"1195_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00002826-200001000-00007","volume":"23","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson\u2019s disease: design and methods of the CALM-PD study. Clin Neuropharmacol 23(1):34\u201344","journal-title":"Clin Neuropharmacol"},{"issue":"Pt 9","key":"1195_CR39","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/brain\/awf214","volume":"125","author":"F Stocchi","year":"2002","unstructured":"Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson\u2019s disease. Brain 125(Pt 9):2058\u20132066","journal-title":"Brain"},{"key":"1195_CR40","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al (2004) Levodopa and the Progression of Parkinson\u2019s Disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"1195_CR41","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947\u2013954","journal-title":"Lancet"},{"issue":"2","key":"1195_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archneur.63.2.210","volume":"63","author":"K Blindauer","year":"2006","unstructured":"Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S et al (2006) A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 63(2):210\u2013216","journal-title":"Arch Neurol"},{"issue":"4","key":"1195_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M et al (2013) Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomized, double-blind trial. Lancet Neurol 12(4):346\u2013356","journal-title":"Lancet Neurol"},{"issue":"2","key":"1195_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double blind, double-dummy study. Lancet Neurol 13(2):141\u2013149","journal-title":"Lancet Neurol"},{"issue":"2","key":"1195_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha J-F, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators (2016) Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154\u2013165","journal-title":"Lancet Neurol"},{"key":"1195_CR46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1345\/aph.19150","volume":"34","author":"JF Siple","year":"2000","unstructured":"Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK (2000) Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 34:382\u2013385","journal-title":"Ann Pharmacother"},{"key":"1195_CR47","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/mds.21273","volume":"22","author":"R Constantinescu","year":"2007","unstructured":"Constantinescu R, Romer M, Kieburtz K (2007) Malignant melanoma in early Parkinson\u2019s disease: the DATATOP trial. Mov Disord 22:720\u2013722","journal-title":"Mov Disord"},{"issue":"3","key":"1195_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JPD-171263","volume":"8","author":"A Bose","year":"2018","unstructured":"Bose A, Petsko GA, Eliezer D (2018) Parkinson\u2019s disease and melanoma: co-occurrence and mechanisms. J Parkinsons Dis 8(3):385\u2013398","journal-title":"J Parkinsons Dis"},{"key":"1195_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1353-8020(03)00040-3","volume":"9","author":"KH Fiala","year":"2003","unstructured":"Fiala KH, Whetteckey J, Manyam BV (2003) Malignant melanoma and levodopa in Parkinson\u2019s disease: causality or coincidence? Parkinsonism Relat Disord 9:321\u2013327","journal-title":"Parkinsonism Relat Disord"},{"issue":"18","key":"1195_CR50","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1212\/WNL.0b013e3181fb4466","volume":"75","author":"C Pais\u00e1n-Ruiz","year":"2010","unstructured":"Pais\u00e1n-Ruiz C, Houlden H (2010) Common pathogenic pathways in melanoma and Parkinson disease. Neurology 75(18):1653\u20131655","journal-title":"Neurology"},{"issue":"9","key":"1195_CR51","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/mds.21397","volume":"22","author":"J Olsen","year":"2007","unstructured":"Olsen J, Tangerud K, Wermuth L, Frederiksen K, Friis S (2007) Treatment with levodopa and risk for malignant melanoma. Mov Disord 22(9):1252\u20131257","journal-title":"Mov Disord"},{"issue":"1","key":"1195_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1353-8020(03)00058-0","volume":"10","author":"H Miwa","year":"2003","unstructured":"Miwa H, Kondo T (2003) Hair loss induced by dopamine agonist: case report and review of the literature. Parkinsonism Relat Disord 10(1):51\u201352","journal-title":"Parkinsonism Relat Disord"},{"key":"1195_CR53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1600-0625.1999.tb00382.x","volume":"8","author":"EMJ Peters","year":"1999","unstructured":"Peters EMJ, Maurer M, Botchkarev VA, Gordon DS, Paus R (1999) Hair growth-modulation by adrenergic drugs. Exp Dermatol 8:274\u2013281","journal-title":"Exp Dermatol"},{"key":"1195_CR54","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S0002-9440(10)64295-2","volume":"162","author":"K Foitzik","year":"2003","unstructured":"Foitzik K, Krause K, Nixon AJ, Ford CA, Ohnemus U, Pearson AJ et al (2003) Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen. Am J Pathol 162:1611\u20131621","journal-title":"Am J Pathol"},{"issue":"1\u20133","key":"1195_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/00207459108985463","volume":"59","author":"J Horvat","year":"1991","unstructured":"Horvat J, Stoji\u0107 Z, Jankovi\u0107 BD (1991) Effect of dopamine, L-dopa, carbidopa and L-dopa\/carbidopa on arthus and delayed hypersensitivity skin reactions in the rat. Int J Neurosci 59(1\u20133):199\u2013203","journal-title":"Int J Neurosci"},{"issue":"2","key":"1195_CR56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","volume":"114","author":"SG Brown","year":"2004","unstructured":"Brown SG (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114(2):371\u2013376","journal-title":"J Allergy Clin Immunol"},{"issue":"1090","key":"1195_CR57","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/postgradmedj-2016-133990","volume":"92","author":"CE Cicero","year":"2016","unstructured":"Cicero CE, Nicoletti A, Mostile G, Zappia M (2016) A case of severe leg oedema in a patient with Parkinson\u2019s disease treated with pramipexole. Postgrad Med J 92(1090):484","journal-title":"Postgrad Med J"},{"key":"1195_CR58","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1038\/ctg.2016.19","volume":"7","author":"M Epstein","year":"2016","unstructured":"Epstein M, Johnson DA, Hawes R, Schmulewitz N, Vanagunas AD, Gossen ER et al (2016) Long-term PEG-J tube safety in patients with advanced Parkinson\u2019s disease. Clin Transl Gastroenterol 7:e159","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01195-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-019-01195-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01195-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T19:37:14Z","timestamp":1595360234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-019-01195-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1007\/s13760-019-01195-3","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"My work compose a review of studies without inclusion of patients details that could lead to patients identification. For this type of study\/report formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}